Risk-sharing agreements (RSAs), especially performance-based, are only growing in popularity among payers, health technology assessment (HTA) agencies, and manufacturers, as they provide common grounds to make new medicines (even more for high-cost ones) available to patients that otherwise wouldn’t be at the time of product launch when limited real-world data are available. HTA outcomes help […]
Risks and Solutions for High-cost Therapies In the last few years, we have seen novel therapies for some complex, rare, and even previously untreatable diseases being approved – Brineura for a rare disorder of the brain, Luxturna for a specific kind of retinal dystrophy, Zolgensma for spinal muscular atrophy, etc. These drugs offer a huge […]
Value-based healthcare (VBH) as a concept was introduced in 2006 by Porter and Teisberg1, though facets of this concept have been around for much longer. Value-based healthcare delivery model is a framework that encourages healthcare providers to focus on quality than quantity. A look at the different healthcare systems across the globe immediately makes it […]